Another milestone in field of vaccine
The country's first indigenous vaccine to prevent cervical cancer was launched on Thursday. Serum Institute of India (SII) and Department of Biotechnology (DBT) have jointly developed Quadrivalent Human Papillomavirus Vaccine (QHPV), a vaccine against cervical cancer. The price of this vaccine has been kept between Rs 200-400 and it will be available in the market by the end of the year.
After breast cancer, the highest number of cases of cervical cancer are seen in women. According to doctors, HIV vaccine is already available for cervical cancer, but people are not aware about it. But the first quadrivalent human papillomavirus vaccine will be available at a lower cost than the current vaccine.
How much will it cost
On the occasion of the launch of the vaccine on Thursday, Science and Technology Minister Jitendra Singh said that after Corona, awareness about the vaccine has increased among the people. The first indigenous vaccine to prevent cervical cancer will prove to be helpful for women. Serum Institute of India (SII) CEO Adar Poonawalla said that the price of this vaccine will be kept low. The price of this vaccine can be between Rs 200-400.
More than 3 lakh women have died
Cervical cancer is the fourth most common cancer in women. This cancer develops in the uterus of the woman. According to the World Health Organization (WHO) data, around 5,70,000 women worldwide were diagnosed with cervical cancer in 2018, and around 3,11,000 women died of the disease.
Deaths will be curbed
Experts have expressed hope that it will be implemented in national HPV vaccination strategies. There are currently two vaccines for cervical cancer worldwide. The first is the quadrivalent vaccine and the second is the bivalent vaccine. The vaccine which Serum has prepared. It is based on VLP similar to Hepatitis B vaccine. Doctors say that the arrival of this vaccine will help in the prevention of cervical cancer and the deaths due to this cancer will be reduced.
The country's first indigenous vaccine to prevent cervical cancer was launched on Thursday. Serum Institute of India (SII) and Department of Biotechnology (DBT) have jointly developed Quadrivalent Human Papillomavirus Vaccine (QHPV), a vaccine against cervical cancer. The price of this vaccine has been kept between Rs 200-400 and it will be available in the market by the end of the year.
Comments
Post a Comment